stagingBackground: Many patients with limited disease (LD) behave similarly to those with extensive disease (ED) from a prognostic point of view. On the other hand, a proportion of patients with ED small-cell lung cancer (SCLC) behave similarly to those with LD. Patients and methods: ...
Small cell lung cancer (SCLC) has been primarily classified as limited or extensive, with limited stage confined to the primary tumor and regional lymph nodes. In the future, the TNM staging system should be integrated into the classification of SCLC. The appropriate staging work-up for patients...
While there has been some push towards the use of TNM staging in SCLC in recent years, the two-stage limited-stage and extensive-stage disease format remains most commonly used because it is functionable and does not usually alter clinical management in most cases, especially as the majority ...
Molecular staging of non-small cell lung cancer according to K-ras genotypes. We have previously demonstrated a strong association between K-ras gene mutations, as determined by PCR followed by allele-specific oligonucleotide hybridi... R Rosell,M Monzó,A Pifarré,... - 《Clinical Cancer ...
Small cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer characterized by rapid tumor growth and early metastasis. Accurate prediction of prognosis and therapeutic response is crucial for optimizing treatment strategies and improving patient outcomes. In this study, we conducted a ...
Lung cancer staging I 58 (41.7%) II 35 (25.2%) III 39 (28.1%) IV 7 (5.0%) Pathological type SCC 81 (58.3%) Adenocarcinoma 40 (28.8%) Large cell carcinoma 4 (2.9%) NSCLC NOS/mixed 12 (8.6%) NSCLC others 2 (1.4%) Grade G1 16 (11.5%) G2 57 (41.0%) G3 47 (33.8%...
The aim of this study was to compare the survival rates of non-small cell lung cancer (NSCLC) with interlobar pleural invasion (IPI) with that of patients with other T2 and T3 diseases according to the seventh TNM staging system. One thousand and one patients with pathologic T2 and T3 NSC...
We previously proposed an immune cell score (tumour node metastasis (TNM)-Immune cell score) classifier as an add-on to the existing TNM staging system for non-small cell lung cancer (NSCLC). Herein, we examined how to reliably assess a tertiary lymphoid structure (TLS) score to refine the...
Although SCLC only accounts for 13–20% of all lung cancers [3], but it is still responsible for up to 40,000 deaths every year all over the world [4]. According to the new tumor-node-metastasis (TNM) version 7 staging system, Extensive-stage small-cell lung cancer (ES-SCLC) is ...
OS, overall survival; SCLC, small cell lung cancer Full size image The Harrell’s C-index for the established nomogram (0.618, 95% CI 0.571–0.665) was significantly higher than that of the TNM staging system (0.548, 95% CI 0.505–0.591; p < 0.001). DCA curve confirmed the clinical ...